A new peer-reviewed study highlights the TUSC2 tumor suppressor gene's crucial role in maintaining mitochondrial function, protein homeostasis, and synaptic pathways in the brain, with significant sex-specific differences observed in mice. Loss of TUSC2 disrupts these processes more in males, and human data shows TUSC2 levels decline with age and Alzheimer's disease, suggesting its importance in brain health. While the study focused on aging and not treatment, it expands understanding of TUSC2 beyond cancer, potentially guiding future therapies for age-related cognitive disorders. Genprex, the company behind the gene, continues to develop related cancer therapies.
Genprex's new preclinical data on the TUSC2 gene comes as 71 of 150 Health-sector US stocks on Pluang rose today. For readers following this sector, here is Pluang's market snapshot as of Oct 21, 2026 18:11 WIB: ROIV (Roivant Sciences Ltd.) gained 5.70% to USD 36.91 with a typical hold time of 9 days; DHR (Danaher Corporation) fell 5.32% to USD 212.10 with 79% sell order activity and a 69-day hold time; TWST (Twist Bioscience Corp) dropped 3.93% to USD 137.09 but saw 100% buy order activity and a 27-day hold time.
The Human Feedback Foundation, supported by RBC, has launched the Agentic AI Design Exchange, a national program aimed at helping Canadian nonprofits design, build, and deploy AI agents responsibly. Funded through RBC's Stronger Nonprofits Program, t...
Satellos Bioscience Inc., a clinical-stage company focused on treatments for degenerative muscle diseases, announced its management will participate in two investor conferences in November: the Guggenheim Healthcare Innovation Conference on Nov 9 in ...
YYForce Inc. has purchased 20 wearable data collection systems to gather real task data from hotel room service at Novotel Singapore. This project aims to record and analyze experienced staff performing tasks like bed-making, towel folding, and clean...
The global digital health and remote patient monitoring market is projected to grow from $26.8 billion in 2025 to $80.8 billion by 2031, at a compound annual growth rate of 20.2%. This growth is driven by increasing demand for chronic disease managem...
The global private credit and alternative lending market, valued at $2.31 trillion in 2026, is expected to grow at a 7.8% CAGR to reach $3.36 trillion by 2031. Recent liquidity pressures in 2025, triggered by bankruptcies and AI sector concerns, caus...
